학술논문
Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial
Document Type
Article
Author
Rocconi, Rodney P; Grosen, Elizabeth A; Ghamande, Sharad A; Chan, John K; Barve, Minal A; Oh, Jonathan; Tewari, Devansu; Morris, Peter C; Stevens, Erin E; Bottsford-Miller, Justin N; Tang, Min; Aaron, Phylicia; Stanbery, Laura; Horvath, Staci; Wallraven, Gladice; Bognar, Ernest; Manning, Luisa; Nemunaitis, John ; Shanahan, David; Slomovitz, Brian M; Herzog, Thomas J; Monk, Bradley J; Coleman, Robert L
Source
In The Lancet Oncology December 2020 21(12):1661-1672
Subject
Language
ISSN
1470-2045